Jiskyn (Bendamustine Hydrochloride)

Bendamustine hydrochloride creates covalent cross‑links within DNA strands, preventing DNA replication and transcription. This interference halts cell‑cycle progression, particularly at the G2/M checkpoint, and triggers programmed cell death (apoptosis) in rapidly dividing malignant lymphoid cells.

The exact dose of Jiskyn is determined by the prescribing oncologist based on the patient’s weight, disease stage, and overall health. Dosing regimens are individualized and should follow the latest clinical guidelines and the prescriber’s judgment.

Bendamustine hydrochloride is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To request Jiskyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Jiskyn (bendamustine) belongs to the alkylating agent class and offers a distinct DNA‑cross‑linking mechanism compared with agents such as rituximab (a monoclonal antibody) or fludarabine (a purine analogue). Clinical studies show comparable efficacy in certain regimens, with a different side‑effect profile that may be advantageous for patients intolerant to alternative therapies.

Jiskyn should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it appears discolored or if the temperature has been exceeded.

Jiskyn is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, according to the dosing schedule prescribed by the treating oncologist.

The most serious risks include severe infections due to neutropenia, tumor lysis syndrome, secondary malignancies, and rare pulmonary toxicity. Patients should be closely monitored for signs of infection, respiratory distress, and abnormal laboratory values throughout treatment.

Jiskyn is contraindicated in patients with known hypersensitivity to bendamustine or any component of the formulation, those with active severe infections, and pregnant or breastfeeding women. Caution is also advised for individuals with significant hepatic or renal impairment.